AU5656896A - Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy - Google Patents

Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy

Info

Publication number
AU5656896A
AU5656896A AU56568/96A AU5656896A AU5656896A AU 5656896 A AU5656896 A AU 5656896A AU 56568/96 A AU56568/96 A AU 56568/96A AU 5656896 A AU5656896 A AU 5656896A AU 5656896 A AU5656896 A AU 5656896A
Authority
AU
Australia
Prior art keywords
combinations
cancer therapy
pkc modulators
oestrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56568/96A
Inventor
Derek Crowther
Gordon Charles Jayson
Alan Thomson Mcgown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of AU5656896A publication Critical patent/AU5656896A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
AU56568/96A 1995-05-11 1996-05-10 Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy Abandoned AU5656896A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9509572.5A GB9509572D0 (en) 1995-05-11 1995-05-11 Cancer therapy
GB9509572 1995-05-11
PCT/GB1996/001120 WO1996035417A1 (en) 1995-05-11 1996-05-10 Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy

Publications (1)

Publication Number Publication Date
AU5656896A true AU5656896A (en) 1996-11-29

Family

ID=10774317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56568/96A Abandoned AU5656896A (en) 1995-05-11 1996-05-10 Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy

Country Status (3)

Country Link
AU (1) AU5656896A (en)
GB (1) GB9509572D0 (en)
WO (1) WO1996035417A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
CA2652783C (en) 2006-05-22 2015-07-14 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
EP2754448A3 (en) 2007-02-09 2014-12-24 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
KR101510646B1 (en) 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 Method for the preparation of therapeutically valuable triphenylbutene derivatives
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827974A1 (en) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh COMBINATION PREPARATIONS OF PROTEINKINASE-C INHIBITORS WITH LIPIDS, LIPID ANALOGS, CYTOSTATICA OR INHIBITORS OF PHOSPHOLIPASES

Also Published As

Publication number Publication date
GB9509572D0 (en) 1995-07-05
WO1996035417A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
PL326653A1 (en) Application of epinastin in pain relieving treatments
AU1372897A (en) 2-amino-heterocycles and therapeutic uses therefor
AU7272196A (en) Use of hyaluronan in gene therapy
HUP9901908A3 (en) P16 expression constructs and their application in cancer therapy
AU5656896A (en) Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy
AU7127196A (en) Nanoparticles in photodynamic therapy
IL118119A0 (en) Azacycloalkane derivatives their preparation and their application in therapy
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
AU7216996A (en) A paf-acetylhydrolase and use in therapy
ZA964563B (en) Isoindole derivatives their preparation and their application in therapy
AU7674896A (en) Adenovirus-antisense k-ras expression vectors and their application in cancer therapy
AU4202096A (en) The use of sertraline to treat cancer patients
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU7139996A (en) Mercaptoamide derivatives and their therapeutic use
GB9514816D0 (en) Substances and their medical use
AU5697996A (en) Peptidyl compounds and their therapeutic use
AU1717997A (en) Disposable applicator and kit
AU6390596A (en) C-cam expression constructs and their application in cancer therapy
AU5554598A (en) Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
AU5001196A (en) Anionic oxygen radicals containing therapeutic agents and th eir use in pain relief
AU6388396A (en) Electromagnetic therapeutic treatment device and methods of using same
AU5841696A (en) Preparation and use of contrast agents